pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Characteristics of patients using drugs

Items efonidipine (n=25) cilnidipine (n=28) P value
Age (years) 59.4 ± 13.2 59.5 ± 12.7 0.969
Sex (male) (n, (%)) 18 (72.0) 20 (71.4) 0.963
Diabetes mellitus (n, (%)) 18 (72.0) 11 (39.3) 0.017
Hypertension (n, (%)) 5 (20.0) 11 (39.3) 0.127
IgA nephropathy (n, (%)) 3 (12.0) 1 (3.6) 0.333
Others* (n, (%)) 0 (0.0) 7 (25.0) 0.011
Height (cm) 165.8 ± 10.1 164.7 ± 8.7 0.672
Weight (kg) 66.6 ± 13.1 68.6 ± 16.8 0.624
Systolic blood pressure (SBP) (mmHg) 143.4 ± 16.9 146.9 ± 22.5 0.530
Diastolic blood pressure (DBP) (mmHg) 82.2 ± 13.8 83.3 ± 14.4 0.774
Serum creatinine (SCr) (mg/dl) 2.7 ± 1.0 3.0 ± 1.6 0.929
Blood urea nitrogen (BUN) (mg/dl) 42.6 ± 12.7 49.7 ± 27.2 0.247
Urine protein/creatinine (P/C) ratio (mg/mg) 4.9 ± 3.7 1.9 ± 2.9 0.003
GFR (mL/min/1.73 m2) 26.7 ± 10.2 26.9 ± 12.9 0.962
Combined antihypertensive medication
ARB or ACE inhibitors (n, (%)) 25 (100.0) 28 (100) 0.613
Other CCB (n, (%)) 8 (32.0) 5 (17.9) 0.232
Beta-blockers (n, (%)) 7 (28.0) 16 (57.1) 0.033
Diuretics (n, (%)) 16 (64.0) 16 (57.1) 0.610

* others: lupus nephritis, nephrotic syndrome, unspecified chronic kidney disease

ARB, angiotensin receptor antagonist; ACE, angiotensin converting enzyme; CCB, calcium channel blocker; GFR, glomerular filtration rate

Korean J Clin Pharm 2020;30:259-63 https://doi.org/10.24304/kjcp.2020.30.4.259
© 2020 Korean J Clin Pharm